4basebio annual ebitda
2022
2023
2024
2025
4basebio EBITDA Growth & History (4BB)
4basebio's calculated EBITDA was −£15.6M for fiscal 2025.
View full 4basebio company overview4basebio annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −£15.6M | −£4.6M | — |
| 2024 | 2024-12-31 | −£11.0M | −£3.6M | — |
| 2023 | 2023-12-31 | −£7.3M | −£1.9M | — |
| 2022 | 2022-12-31 | −£5.4M | — | — |
4basebio ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, 4basebio's ebitda decreased from −£5.4M to −£15.6M, a change of −£10.2M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review 4basebio source filings ↗Community posts
4basebio expands synthetic-DNA manufacturing for personalised mRNA medicines
4basebio announced an expansion of its DNA offering on 7 September 2026. Manufacturing changes The company has added suite capacity and enhanced process controls and quality systems across its Cambridge high-quality and current-GMP operatio ...